Medical methods for first trimester abortion.
Jing Zhang,Kunyan Zhou,Dan Shan,Xiaoyan Luo
DOI: https://doi.org/10.1002/14651858.CD002855.pub5
IF: 8.4
2022-05-26
Cochrane Database of Systematic Reviews
Abstract:Medical abortion became an alternative method of pregnancy termination following the development of prostaglandins and antiprogesterone in the 1970s and 1980s. Recently, synthesis inhibitors of oestrogen (such as letrozole) have also been used to enhance efficacy. The most widely researched drugs are prostaglandins (such as misoprostol, which has a strong uterotonic effect), mifepristone, mifepristone with prostaglandins, and letrozole with prostaglandins. More evidence is needed to identify the best dosage, regimen, and route of administration to optimise patient outcomes. This is an update of a review last published in 2011. To compare the effectiveness and side effects of different medical methods for first trimester abortion. We searched CENTRAL, MEDLINE, Embase, Global Health, and LILACs on 28 February 2021. We also searched Clinicaltrials.gov and the World Health Organization's (WHO) International Clinical Trials Registry Platform, and reference lists of retrieved papers. We considered randomised controlled trials (RCTs) that compared different medical methods for abortion before the 12th week of gestation. The primary outcome is failure to achieve complete abortion. Secondary outcomes are mortality, surgical evacuation, ongoing pregnancy at follow‐up, time until passing of conceptus, blood transfusion, side effects and women's dissatisfaction with the method. Two review authors independently selected and evaluated studies for inclusion, and assessed the risk of bias. We processed data using Review Manager 5 software. We assessed the certainty of the evidence using the GRADE approach. We included 99 studies in the review (58 from the original review and 41 new studies). 1. Combined regimen mifepristone/prostaglandin Mifepristone dose: high‐dose (600 mg) compared to low‐dose (200 mg) mifepristone probably has similar effectiveness in achieving complete abortion (RR 1.07, 95% CI 0.87 to 1.33; I 2 = 0%; 4 RCTs, 3494 women; moderate‐certainty evidence). Prostaglandin dose: 800 μg misoprostol probably reduces abortion failure compared to 400 μg (RR 0.63, 95% CI 0.51 to 0.78; I 2 = 0%; 3 RCTs, 4424 women; moderate‐certainty evidence). Prostaglandin timing: misoprostol administered on day one probably achieves more success on complete abortion than on day three (RR 1.94, 95% CI 1.05 to 3.58; 1489 women; 1 RCT; moderate‐certainty evidence). Administration strategy: there may be no difference in failure of complete abortion with self‐administration at home compared with hospital administration (RR 1.63, 95% CI 0.68 to 3.94; I 2 = 84%; 2263 women; 4 RCTs; low‐certainty evidence), but failure may be higher when administered by nurses in hospital compared to by doctors in hospital (RR 2.69, 95% CI 1.39 to 5.22; I 2 = 66%; 3 RCTs, 3056 women; low‐certainty evidence). Administration route: oral misoprostol probably leads to more failures than the vaginal route (RR 2.38, 95% CI 1.46 to 3.87; I 2 = 39%; 3 RCTs, 1704 women; moderate‐certainty evidence) and may be associated with more frequent side effects such as nausea (RR 1.14, 95% CI 1.03 to 1.26; I 2 = 0%; 2 RCTs, 1380 women; low‐certainty evidence) and diarrhoea (RR 1.80 95% CI 1.49 to 2.17; I 2 = 0%; 2 RCTs, 1379 women). Compared with the vaginal route, complete abortion failure is probably lower with sublingual (RR 0.68, 95% CI 0.22 to 2.11; I 2 = 59%; 2 RCTs, 3229 women; moderate‐certainty evidence) and may be lower with buccal administration (RR 0.71, 95% CI 0.34 to 1.46; I 2 = 0%; 2 RCTs, 479 women; low‐certainty evidence), but sublingual or buccal routes may lead to more side effects. Women may experience more vomiting with sublingual compared to buccal administration (RR 1.33, 95% CI 1.01 to 1.77; low‐certainty evidence). 2. Mifepristone alone versus combined regimen The efficacy of mifepristone alone in achieving complete abortion compared to combined mifepristone/prostaglandin up to 12 weeks is unclear (RR of failure 3.25, 95% CI 0.81 to 13.09; I 2 = 83%; 3 RCTs, 273 women; very low‐certainty evidence). 3. Prostaglandin alone versus combined regimen Nineteen studies compared prostaglandin alone to a combined regimen (prostaglandin combined with mifepristone, letrozole, estradiol valerate, tamoxifen, or methotrexate). Compared to any of the combination regimens, misoprostol alone may increase the risk for failure to achieve complete abortion (RR of failure 2.39, 95% CI 1.89 to 3.02; I 2 = 64%; 18 RCTs, 3471 women; low‐certainty evidence), and with more diarrhoea. 4. Prostaglandin alone (route of administration) Oral misoprostol alone may lead to more failures in complete abortion than the vaginal route (RR 3.68, 95% CI 1.56 to 8.71, 2 RCTs, 216 women; low‐certainty evidence). Failure to achieve complete abortion may be slightly reduced with sublingual comp -Abstract Truncated-
medicine, general & internal